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Abstract
Although culture-independent techniques have shown that the lungs are not sterile, little is known about the lung
microbiome in chronic obstructive pulmonary disease (COPD). We used pyrosequencing of 16S amplicons to analyze the
lung microbiome in two ways: first, using bronchoalveolar lavage (BAL) to sample the distal bronchi and air-spaces; and
second, by examining multiple discrete tissue sites in the lungs of six subjects removed at the time of transplantation. We
performed BAL on three never-smokers (NS) with normal spirometry, seven smokers with normal spirometry (‘‘heathy
smokers’’, HS), and four subjects with COPD (CS). Bacterial 16 s sequences were found in all subjects, without significant
quantitative differences between groups. Both taxonomy-based and taxonomy-independent approaches disclosed
heterogeneity in the bacterial communities between HS subjects that was similar to that seen in healthy NS and two mild
COPD patients. The moderate and severe COPD patients had very limited community diversity, which was also noted in 28%
of the healthy subjects. Both approaches revealed extensive membership overlap between the bacterial communities of the
three study groups. No genera were common within a group but unique across groups. Our data suggests the existence of
a core pulmonary bacterial microbiome that includes Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Haemophilus,
Veillonella, and Porphyromonas. Most strikingly, there were significant micro-anatomic differences in bacterial communities
within the same lung of subjects with advanced COPD. These studies are further demonstration of the pulmonary
microbiome and highlight global and micro-anatomic changes in these bacterial communities in severe COPD patients.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive
and potentially fatal lung disease that is projected to be responsible
for the fifth largest burden of disease worldwide by 2020 [1,2].
COPD is characterized by largely irreversible airflow limitation,
mucus hypersecretion, small airway fibrosis, and destruction of the
alveolar space (emphysema) [3]. In developed nations, the leading
cause of COPD is tobacco smoke exposure, predominately direct,
whereas in developing nations indoor air pollution from
combustion of biomass fuel also contributes significantly [4]. Not
all smokers develop COPD, but why some do is not currently
known. Because no current treatments halt COPD progression,
new insights into its pathogenesis are urgently needed.
From the initial description of COPD as a distinct clinical
condition responsible for productive cough and shortness of breath
in patients without tuberculosis [5], there has been considerable
controversy about the role of lower respiratory tract bacteria in its
pathogenesis. This is the case both for its prolonged early
asymptomatic phase and, until recently, for the acute exacerba-
tions that punctuate its later stages [6], which can induce
accelerated and sustained loss of lung function [7]. In part, this
controversy arose because classical, culture-based studies suggested
that the lungs of healthy individuals were sterile [8,9,10], while the
lungs of COPD patients were believed to be colonized. More
recently, culture-independent microbiological techniques demon-
strated that the lungs are not sterile during health and documented
changes in the lung microbiome in several lung diseases
[11,12,13,14,15]. Nevertheless, the role of the lung bacterial
microbiome in COPD pathogenesis and progression remains
undefined.
Our two objectives addressed two gaps in the understanding of
the pulmonary microbiome as related to smoking and COPD. The
first was to assess the lung microbiome in smokers with neither
signs of disease nor decreased lung function (‘‘healthy’’ smokers)
through analysis of bronchoalveolar lavage (BAL) fluid, which
samples a broad region of lungs, and compare this to healthy non-
smokers. The second objective was to determine whether
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16384pulmonary microanatomic/microenvironmental disparities lead to
differences in the structure of localized bacterial communities in
COPD, through analysis of multiple sample sites from surgical
explants. We analyzed both types of samples by massively parallel
pyrosequencing of bacterial 16S amplicons, a technique that
provides a culture-independent analysis of the resident pulmonary
microbiome and offers a breadth of analysis not previously
available for studies of pulmonary biology and disease.
Methods and Materials
Ethics Statement
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. The study
protocol was approved by the institutional review boards of the
University of Michigan Healthcare System and the Ann Arbor
Veterans Affairs Healthcare System. All patients provided written
informed consent. The institutional review boards have examined
the protocols and certified that ‘‘The risks are reasonable in
relation to benefits to subjects and the knowledge to be gained.
The risks of the study have been minimized to the extent possible.’’
Subject Enrollment – Patient populations
Specimens were obtained from subjects enrolled in an
observational study registered with ClinicalTrials.gov as
NCT00281229. Bronchoalveolar lavage (BAL) samples (n=14)
came from volunteers who underwent research bronchoscopy at
the VA Ann Arbor Healthcare System. Surgical specimens (n=8)
were obtained from six patients undergoing clinically-indicated
lung transplantation for COPD at the University of Michigan
Health Care System. All subjects underwent pre-procedure
spirometry, PA and lateral chest radiogram, electrocardiogram,
complete blood count and automated chemistry analysis, prospec-
tively collected medication history, and clinical evaluation; surgical
participants also underwent computerized tomography (CT) of the
chest and full pulmonary function testing. We excluded subjects
who had mental incompetence or active psychiatric illness
precluding informed consent; asthma as primary clinical pulmo-
nary diagnosis; cystic fibrosis, clinically significant bronchiectasis
or other inflammatory or fibrotic lung diseases; and those taking
prednisone .20 mg daily.
Spirometry was expressed as a function of appropriate predicted
equations for the included population [16,17]. We categorized
subjects using the spirometric classification of the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) [18]. For the BAL
cohort analyses, subjects were segregated into three groups: healthy
smokers (HS) exhibiting no evidence of underlying lung disease,
post-bronchodilator FEV1/FVC.0.70 and FEV1%.80% pre-
dicted; never smokers (NS) having no smoking history or evidence
of lung disease, post-bronchodilator FEV1/FVC.0.70 and
FEV1%.80% predicted; COPD subjects (CS) having a post-
bronchodilator FEV1/FVC,0.70 and FEV1%,80% predicted.
Samples
Volunteer subjects underwent fiberoptic bronchoscopy under
moderate conscious sedation according to published guidelines
[19] using nebulized and instilled lidocaine, intravenous fentanyl,
midazolam, and in some cases, diphenhydramine. Initially, we
performed bronchoscopy via the nostril, which was anesthetized
using viscous lidocaine (2%), but for the last 11 procedures,
bronchoscopy was performed via the mouth to minimize
contamination. The bronchoscope was successively wedged into
a single subsegment of the right middle lobe and the lingula, each
of which were lavaged with a total of 120 ml normal saline, heated
to body temperature, which was removed using manual suction on
a 30 ml syringe. The total recovered volume was pooled and
transported to the laboratory immediately where 15 ml of
unprocessed BAL fluid was reserved for microbiome analysis,
before the remainder was processed for other research studies.
BALs were divided evenly into 2 ml Eppendorf tubes, spun at
Table 1. Bronchoalveolar Lavage Patient Cohort.
Group Subject # Age Ethnicity Gender
Smoking
history
FEV1
(%pred) FEV1/FVC Medications Approach
Current
Smoker
HS 1 53 C
1 F 20 98 0.77 N Oral Yes
24 5 C
1 F 16 103 0.80 N Nasal Yes
34 5 C
1 M 20 114 0.93 N Nasal Yes
4 49 AI/NA
2 F 40 102 0.76 N Nasal Yes
55 0 A A
3 M 15 99 0.77 N Nasal Yes
64 7 C
1 F 39 96 0.76 N Nasal Yes
76 6 C
1 M 32 110 0.80 N Nasal No
CS 1 54 C
1 M 120 79 0.63 ICS
4/LAB
5 Nasal No
26 2 C
1 M 68 78 0.68 N Nasal Yes
34 0 A A
3 M 25 79 0.67 N Oral Yes
46 0 C
1 M 41 25 0.41 ICS
4/LAB
5 Oral No
NS 1 48 C
1 F 0 105 0.86 N Nasal No
27 8 C
1 F 0 83 0.77 N Nasal No
35 8 C
1 F 0 142 0.80 N Nasal No
1=Caucasian;
2=American Indian/Native American;
3=African American;
4=Inhaled Corticosteroids;
5=Long Acting Beta-Agonists.
doi:10.1371/journal.pone.0016384.t001
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supernatants discarded, the pellets snap frozen in liquid nitrogen,
and stored at -80uC.
Lung explants were obtained immediately following removal
and were sterilely dissected in the hospital pathology lab in a
laminar flow hood, using appropriate biosafety precautions. The
lung explant was cut either sagittally or coronally to expose the
airways for sampling. Airways were isolated starting proximally,
and 1 cm
2 tissue samples were sequentially collected from the
segmental and distal portions of the upper, middle, and lower
lobes, and processed separately. The anatomic location of
sampling was carefully recorded to allow radiographic correlation
with airway structure.
Computed tomography
High resolution computed tomography (HRCT) images were
acquired using 64-row detector CT scanners (GEMedical
Imaging, Wisconsin, USA). After initial anterior-posterior and
lateral planning images, supine end-inhalation axial images were
obtained in a volumetric fashion. No intravenous contrast material
was administered. The images obtained were 1.25 mm thick
images obtained at every 1.25 mm interval with a pitch of1.375:1,
using 120 kvp, variable tube currents (ranged between 80-375 mA
based on body habitus), 0.5-0.6 s tube rotation speed and with a
noise index of 22. These images were reconstructed using bone
algorithm and viewed using routine lung window settings (window
width of 1300 HU and window level of -600 HU).
DNA Isolation
To extract DNA from the BAL samples, tubes containing
sample pellets (corresponding to 5 ml BAL) were suspended in a
total of 500 ml Bacterial Lysis Buffer (BLB) (Roche Diagnostics),
then transferred to 2 ml bead beating tubes (Mo Bio). Samples
were homogenized in a Mini Bead-Beater 16 (Biospec) for
1 minute followed by centrifugation for 1 minute at 13,000 rpm
in a fixed angle microcentrifuge (Microfuge 18, Beckman Coulter,
Indianapolis, IN). Subsequently, 40 ml of proteinase K was added
to each sample, which was then incubated for 10 minutes at 65u,
followed by a second bead-beating for 1 minute, then centrifuga-
tion at full speed for 1 minute. Finally, tubes were incubated for
10 minutes at 95uC. DNA was harvested from these lysates using
the MagNA Pure Compact system and Nucleic Acid Isolation Kit
I (Roche, Indianapolis, IN). DNA concentration was quantified
using the NanoDropH ND-1000 Spectrophotometer (Nanodrop
Technologies). We isolated DNA from lung tissue samples by the
same procedure, except that the duration of each bead beating
step was increased to 2 minutes.
16S Quantitative PCR
qPCR was used to quantify the 16S content of our samples.
Reactions were performed on a Lightcycler 480 (Roche) using the
following protocol: 50uC for 2 min, 95uC for 10 min, followed by
45 cycles of 95uC for 15 sec, and 60uC for 60 sec. Readings were
taken in single acquisition mode. The primers and probes
consisted of a forward-primer TCC TAC GGG AGG CAG
CAG T, the reverse-primer GGA CTA CCA GGG TAT CTA
ATC TT, and the 16S specific probe 59-FAM/CGT ATT ACC
GCG GCT GCT GGC AC/39-TAMSp. A standard curve was
constructed using 24 two-fold dilutions of Helicobacter hepaticus DNA
(a bacterium known to have only a single copy of the 16S gene in
its genome) beginning at 1000 ng. Samples were run in duplicate
and at 1:10 and 1:100 fold dilutions.
454 Pyrosequencing
The bacterial tag-encoded FLX-Titanium amplicon pyrose-
quencing (bTEFAP) method targeting the V1-V3 variable regions
of 16S rRNA was used to create amplicon libraries [20]. V1-V3
primer sets corresponded to 27F (59- GAGTTTGATCNTGGCT-
CAG-39) and 519R (59- GWNTTACNGCGGCKGCTG-39),
along with appropriate sample nucleotide bar codes and the
Roche A & B primers. The pyrosequencing was performed
following established protocols [21].
Table 2. Explant Cohort (CS).
Subject # Age Ethnicity Gender Smoking history FEV1 (%pred) FEV1/FVC Medcations
5 (SLT
6)6 6C
1 MN o ( .6 Months) 18 0.22 ICS
4/LAB
5
6( B L T
7)5 7C
1 MN o ( .6 Months) 13 0.17 ICS
4/LAB
5
7 (BLT) 62 C
1 MN o ( .6 Months) 15 19 ICS
8 (SLT) 59 C
1 MN o ( .6 Months) 9 16 None
9 (SLT) 59 C
1 MN o ( .6 Months) 25 44 ICS/LAB
10 (SLT) 64 C
1 MN o ( .6 Months) 16 33 ICS/LAB
6=Single Lung Transplant;
7=Bilateral Lung Transplant.
doi:10.1371/journal.pone.0016384.t002
Figure 1. 16S qPCR of BAL Samples. The number of copies of
bacterial 16S per ml of BAL fluid was measured by qPCR (as described in
Methods and Materials). The samples were divided into three groups:
healthy smoker (HS), COPD subject (CS), and never-smoker (NS); the
individual samples are displayed along the x-axis (Mean 6 SEM).
Samples where run in duplicate with two 10-fold dilutions.
doi:10.1371/journal.pone.0016384.g001
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Taxonomy. A locally run version of RDP Classifier (http://
rdp.cme.msu.edu) was used for phylotyping 16S rDNA
sequences. Sequences containing fewer than 50 nucleotides, and
sequences without a valid barcode or those that had the barcode
in the wrong position, were removed as low-quality reads. A
confidence cut-off of 50% was used to produce accurate
taxonomic identifications [22]. Data tables were constructed
from the Classifier output and analyzed using several custom R
scripts and the vegan package for R (http://CRAN.R-project.
org/package=vegan) [23].
Operational Taxonomic Units (OTUs). The open-source,
platform-independent, community-supported software program,
mothur (http://www.mothur.org; [24]), was used to process and
Figure 2. Taxonomic Classification of Bacterial Communities Present in the BAL. The V1-V3 region of the bacterial 16S genes were
sequenced using 454-pyrosequencing and taxonomically classified using RDP Classifier. A. Phylum level classification of the 16S amplicons presenti n
a given subject. B. Genus level classification of these amplicons. The numbers at the bottom of each pie chart identify the organisms which can be
found in Table 3.
doi:10.1371/journal.pone.0016384.g002
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filtered using quality control procedures described above, pre-
clustering, and chimera elimination. 16S rDNA analysis was
performed using an OTU cutoff of 3% and followed the Costello
Stool Analysis example (http://www.mothur.org/wiki/Costello_
stool_analysis).
Statistical analysis
Statistical analyses were performed using Prism 5 (GraphPad
Software) for One-way ANOVA and R (http://www.r-project.
org).
Results
The characteristics of the 14 patients undergoing BAL are
presented in Table 1. The age ranged from 40-78 yrs (median
53.9 yrs) with 7/14 male and 8/14 currently smoking. The six
patients who underwent lung transplantation for advanced COPD
were males with severe airflow obstruction (Table 2). One had
emphysema related to alpha-1 antitrypsin deficiency (CS #6).
To address our first objective of determining if there was a
difference in total bacterial numbers between the three groups, we
isolated total DNA from the BAL pellet after high speed
centrifugation and determined 16S gene copy number by qPCR.
In every sample in our study, significant levels of bacterial 16S
gene signal were detected (Figure 1). There were no significant
differences between the three study groups (Log 16S copy #/ml
BAL: HS, 8.2560.25; CS, 8.1260.40; NS 8.2460.66 mean 6
SEM; p.0.05). Altogether, the levels of bacteria detected in the
BAL fluid of our 14 subjects were consistent with previous
estimates based on sterile brushings of the airways [12]. Thus,
there were significant levels of bacteria in all subjects, without
significant differences between never-smokers and those with end-
stage lung disease.
To compare the bacterial community structure (membership
and diversity) of the resident pulmonary microbiome between
subjects and between groups, we next used 454-pyrosequencing to
analyze 16S amplicon libraries generated from our BAL samples.
Following quality control filtering of the sequences we used RDP-
Classifier [25] to assign taxonomic classifications to the sequences
for ecological analysis. In agreement with our qPCR analysis
(Figure 1), a community of lung-resident bacteria was readily
identifiable in each BAL sample (Figure 2 & Table 3). Virtually
all of the filtered reads (91%61.5% mean 6SEM) could be
classified down to the genus level, irrespective of subject cohort.
The dominant phyla in the lungs of our subjects were the
Proteobacteria, Firmicutes, and Bacteroidetes (Figure 2A). At the
phylum-level, there was heterogeneity in the bacterial communi-
ties between most of the HS group that was similar to that seen in
healthy never-smokers (NS) and our two mild COPD patients
(CS#1&C S #2). By contrast, the moderate and severe COPD
patients (CS#3&C S #4) lacked bacterial community diversity,
Table 3. BAL Abundance Table.
Rank Name
Total #
Sequences
# Subjects
Occurred/Total
1 Pseudomonas 78319 12/14
2 Streptococcus 23253 12/14
3 Prevotella 19916 10/14
4 Fusobacterium 8784 11/14
5 Veillonella 5937 9/14
6 Porphyromonas 4366 8/14
7 Leptotrichia 3801 5/14
8 Haemophilus 2765 8/14
9 Oribacterium 1577 6/14
10 Actinobacillus 1539 4/14
11 Actinomyces 1188 6/14
12 Megasphaera 1017 4/14
13 Sneathia 879 2/14
14 Gemella 828 7/14
15 Tropheryma 783 1/14
16 Neisseria 748 4/14
17 Granulicatella 731 5/14
18 Campylobacter 535 2/14
19 Atopobium 511 3/14
20 Bulleidia 480 4/14
21 Lachnospira 474 3/14
22 Parvimonas 379 3/14
23 Flavimonas 352 3/14
24 Bacteroides 304 2/14
25 Tannerella 262 2/14
26 Hallella 210 3/14
27 Catonella 197 2/14
28 Stenotrophomonas 193 1/14
29 Selenomonas 155 1/14
30 Mycoplasma 130 1/14
31 Peptostreptococcus 124 1/14
32 Aggregatibacter 110 1/14
33 Staphylococcus 108 1/14
34 Cloacibacterium 106 1/14
35 Citrobacter 94 1/14
36 Acidovorax 93 1/14
37 Rothia 93 1/14
38 Flavobacterium 91 1/14
39 Xanthomonas 88 1/14
40 Moryella 82 1/14
41 Anaerococcus 77 1/14
42 Corynebacterium 65 1/14
43 Centipeda 62 1/14
44 Faecalibacterium 62 1/14
45 Acinetobacter 59 1/14
46 Cryobacterium 55 1/14
47 Sphingopyxis 53 1/14
48 Burkholderia 52 1/14
49 Brevundimonas 51 1/14
Rank Name
Total #
Sequences
# Subjects
Occurred/Total
50 Rhodobacter 51 1/14
51 Treponema 51 1/14
doi:10.1371/journal.pone.0016384.t003
Table 3. Cont.
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and one never-smoker (NS#2).
At the genus-level (Figure 2B), the bacterial communities in
the healthy smokers (HS) and never-smokers were fairly diverse
with the exception of one individual in each of the groups (HS#4
and NS#2, respectively). For each phyla present in a sample, there
were typically one to two dominant genera (e.g., Pseudomonas,
Streptococcus, Prevotella, Fusobacterium or Veillonella; Figure 2B and
Table 3). Similar diversity was also seen in the two mild COPD
patients (CS#1&C S #2), but a loss of diversity was observed in
the COPD subjects (CS#3&C S #4) with more severe disease.
Overall, the pulmonary microbiome in our subjects was diverse,
but more limited than is typically found for bacterial communities
in the mouth and intestine [26,27].
Figure 3. Identification of Bacterial Community Membership Overlap in Subject BALs. The relative abundance of each genera present in
the BAL of each subject are plotted together with the numbers along the x-axis corresponding to the rank from Table 3. The study subject is
displayed along the z-axis and the relative abundance (as a percent) is displayed along the y-axis. The genera Pseudomonas, Streptococcus, Prevotella,
Fusobacterium, Veillonella and Prophyromonas are highlighted due to the dominance of these organisms within all of the subjects examined.
doi:10.1371/journal.pone.0016384.g003
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using principal components analysis (PCA, Figure 3A) to create a
community ordination and examine which elements of the
community have the strongest influence in the variation between
subjects. This approach revealed extensive overlap in membership
between the bacterial communities of the HS, CS, and NS groups.
There were no bacteria that were common within a group but
instead unique across groups that would separate one group from
another. Thus, outgrowth from within the community, rather than
invasion, seems plausible in subjects whose pulmonary micro-
biome was dominated by a single bacterial genus.
Our data also suggested that there may be bacteria that
comprise a ‘‘core’’ pulmonary microbiome, i.e., found with very
high frequency (at .1% of all 16 s reads) in the BAL of healthy
subjects. Candidate genera that were found in greater than 75% of
our subjects included Pseudomonas, Streptococcus, Prevotella and
Fusobacterium (Table 3 & Figure 3B). Haemophilus, Veillonella, and
Porphyromonas were also identified in over half of the samples.
We also analyzed the 16S pyrosequencing data by the
complementary approach of self-assembling operational taxonom-
ic unit (OTU) analysis, which eliminates any potential binning
biases inherent in taxonomic methods. For a point of reference, a
3% difference between two full-length 16S sequences is roughly
equivalent to a species level difference at the genomic level [28].
We used this level of similarity to generate OTUs and calculated
diversity indices using the non-parametric form of the Shannon
Diversity index. Consistent with the taxonomic analysis
(Figure 2B), OTU-based analysis (Table 4) confirmed that
there were diverse bacterial communities (higher np Shannon
values indicate higher diversity) in the healthy smokers (HS), which
was similar to that seen in the healthy never-smokers (NS) and our
two mild COPD patients (CS#1&C S #2). This analysis again
identified that the pulmonary microbiome was much less diverse in
the moderate and severe COPD patients (CS#3&C S #4)
(Table 4).
To generate an estimate of the average species richness within
the genera from a subject, we also compared the number of genera
from the classifier-based method to the number of OTU at the 3%
identity level. We limited our analyses to the number of genera
that were present at .1% and the number of OTU present at
.1%, respectively. Importantly, this analysis demonstrated that
species-level diversity within the human lungs is very limited:
approximately two OTU per genera in each subject, with the
notable exception of CS#3 which had 10 (Table 4). Overall, both
OTU and classifier-based approaches demonstrated that the lungs
of all subjects contain a diverse resident bacterial microbiome that
displays only limited richness at the sub-genus level.
To address the critical question of whether the bacteria in the
BAL samples might reflect upper airway contamination of the
bronchoscopes used during the procedure, we sampled multiple
tissue sites from eight COPD lung explants removed during
transplantation (six single and two bilateral transplants). All
tissues sampled from the explanted lungs contained readily
identifiable bacterial communities (Figure 4). Because BAL
samples multiple airways and alveoli distal to a segmental or
subsegmental bronchus, we first combined all of the individual
sequencing reads in silico from all of the tissue samples of single
lobe of the surgical specimens, and performed a separate analysis.
The bacterial community profile of each of the three lobes were
dominated in all three samples by the genus Pseudomonas
(Figure 4A, Tissue), which was very similar to that of the
BAL sample from our severe COPD subject (CS#4) and a
number of others (Figure 2). Thus, direct sampling of explant
tissue demonstrated that the bacterial communities in the BAL
samples were lung-resident microbes and not the result of
bronchoscope contamination.
We next compared individual tissue sites to determine whether
there were micro-anatomic differences in bacterial communities
within the lungs of subjects with advanced COPD. Each lobe had
four to eight distinct tissue sites sampled, for a total of 44 tissue
sites. No bronchiectatic changes were evident in the pre-operative
CT images for any of the tissue sites sampled in these subjects.
Figure 4b demonstrates illustrative CT images of two patients;
similar results were seen in the other four patients (data not
shown). However, despite normal structure, there were sites of
significant differences in bacterial community composition within
the same lung. This was particularly evident in the left upper lobe
from subject CS#6. Haemophilus dominated the community in the
segmental bronchus of the LUL. Stentrophomonas dominated in the
distal bronchus of the LUL. In sharp contrast, Pseudomonas
Table 4. BAL OTU Data.
Subject # OTUs
1.1% of Population Diversity (np Shannon) OTUs
1.1%/Genera.1%
HS#1 25 4.85 25/12
HS#2 17 3.98 9/9
HS#3 3 2.03 3/2
HS#4 31 4.29 31/11
HS#5 16 4.82 16/10
HS#6 15 3.40 15/7
HS#7 14 3.5 14/10
CS#1 20 4.91 20/12
CS#2 15 3.97 17/13
CS#3 10 1.97 10/1
CS#4 5 1.56 5/3
NS#1 18 3.42 18/8
NS#2 6 1.68 6/6
NS#3 12 3.67 12/9
doi:10.1371/journal.pone.0016384.t004
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many others within the same lung. The additional explanted lobes
also displayed micro-anatomic heterogeneity. The most striking
differences were observed between tissue sites in CS#7RL, while
all the tissue sites in CS#8RL were dominated almost entirely by
Pseudomonas (Figure 5). These data demonstrate for the first time
that marked regional differences in the bacterial microbiome can
exist within an individual subject.
We next constructed a furthest-neighbor joining tree, based on
the Bray-Curtis distance, of sampled communities to compare the
beta-diversity (inter-community diversity) between the bacterial
communities of the different sites from CS#5 and CS#6
(Figure 6A). Most of the samples resulted in a low Bray-Curtis
distance, indicating that the samples are more similar to each
other. However, the CS#6 LUL Segmental and CS#6 LUL
Distal samples cluster apart from the main group and from each
other with high Bray-Curtis values, indicating a high degree of
dissimilarity. We again used PCA ordination to identify which
elements were responsible for driving the differences between
individual samples (Figure 6B). This analysis demonstrated that
Figure 4. Bacterial Communities Present in Individual Lung Airways. A. Bacterial community profiles for an entire explanted lung lobe from
subjects with severe COPD. The total aggregate genus level reads of samples taken from the right lung of subject CS#5, the right lung of subject
CS#6, and the left lung of subject CS#6 were analyzed on a per lung basis and compared to the BAL of subject CS#4 (reproduced from Figure 2). B.
Multiple samples were taken from lung explants (right lung, subject CS#5; both lungs, subject CS#6) at the time of elective transplantation. Samples
were harvested from the regions of lung indicated by the arrows on the gray lung schematic. Pie diagrams depict the genus level classification of 16S
sequences, and the CT images demonstrate the absence of bronchiectasis in the airways adjacent to where samples were obtained. The key for the
nine most abundant organisms is provided below the lung schematic. The full community breakdown for each of the airways can be found in Table
S1.
doi:10.1371/journal.pone.0016384.g004
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the dominance of Pseudomonas, Haemophilus,o rSentrophomonas at the
site.
Analysis of OTUs (based on 3% dissimilarity) demonstrated that
significant numeric differences also existed between the number of
OTUs in tissue sites within the same lung and even within the
same lobe (Table 5). One intriguing observation was that in
samples in which there was domination by a single genus
(Pseudomonas), there was often marked heterogeneity in the
numbers of OTUs. For example, we observed this for a number
of regions in the right lobe from CS#5 and in the BAL from
subject CS#3( Figure 2B & Table 3). The OTU and classifier-
based analyses of these samples were consistent with each other
and clearly demonstrated that significant micro-anatomic differ-
ences can exist in bacterial communities within the same lung of
subjects with advanced COPD.
Discussion
This study using massively parallel pyrosequencing of bacterial
16S amplicons provides novel information on the microbiota of a
range of subjects including healthy non-smokers, smokers with
normal lung function, and stable COPD subjects with mild or
severe spirometric disease. We have demonstrated three key
findings. First, the lungs of healthy smokers contain a bacterial
microbiome that is quantitatively significant, diverse (but of limited
membership), and quite distinct from that reported for the oral
cavity or nasopharynx [26]. Second, the diversity of the lung
bacterial microbiome is often lower in subjects with decreased lung
function, most commonly associated with dominance by Pseudo-
monas spp. Third, this is the first study to describe that the
numerous microanatomic sites within the lung can give rise to
significant differences in bacterial community structure.
Our current study has examined the lung microbiome with an
unprecedented depth, averaging ,12,000 sequences per sample.
This markedly greater sequencing depth increases confidence that
we have sufficiently sampled the lungs to characterize the
microbial lung community accurately. Our studies of the BAL
from healthy smokers are consistent with the recent demonstration
of a diverse bacterial lung microbiome in healthy individuals [12],
a study which had ,3,000 sequence reads total for the entire
study.
Importantly, our finding that some smokers had a less diverse
lung microbiota relative to smokers with normal lung function
indicates that alteration in lung microbiota can occur in subjects
with no spirometric evidence of disease. Whether this relative
reduction in diversity is persistent, is an effect of the inflammatory
changes that characterize COPD, or could in part contribute to
disease progression are all questions that will require longitudinal
follow-up in larger groups of subjects. Our results are consistent
with findings at another mucosal site, the gastrointestinal tract,
where decreases in the diversity of the microbiota are associated
with increased incidence of inflammatory bowel disease [30,31].
Lung community dysbiosis could provide the constant inflamma-
tory stimulus that has long been observed in COPD [32]. Thus, in
the lungs, as with other sites on the mucosa, a diverse microbiota
may be important for health, including colonization resistance,
epithelial integrity, and immunoregulation [33,34].
Collectively, our results provide a unifying framework for
characterizing the role of Pseudomonas and Haemophilus in the
development, progression and/or exacerbation of COPD. Prior to
the use of culture-independent techniques, Haemophilus was the
organism most frequently grown from samples of COPD lungs
[35], with Pseudomonas oftentimes noted [36]. The current work
suggests that these organisms are generally present even under
healthy conditions. While larger studies must be performed, our
Figure 5. Bacterial Distribution Throughout COPD Lung Explants. Bacterial communities were characterized in the airways from 5 lobes of 4
lung explants. Multiple samples (4-8) were taken throughout the lung explants at the time of elective transplantation. The barchart depicts the genus
level classification of 16S sequences identified.
doi:10.1371/journal.pone.0016384.g005
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and B. Biplot of the principle components analysis of the normalized bacterial communities from multiple anatomic sites in the lung explants.
doi:10.1371/journal.pone.0016384.g006
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lung’s microbial community is associated with disease.
We have also shown that because of local differences in lung
airway microarchitecture, samples from different airways taken
throughout the lungs can contain very different bacterial
communities. This result was most pronounced in the airways
of the left upper lobe in one transplant recipient (Figure 4)
where the bacterial community was dominated by a bacterial
genera (Haemophilus) that was not detected at high levels in the
other airways. A previous study [12] found a significant
correlation between COPD and the presence of Haemophilus
spp. in sterile brushings of the left upper lobes. At first pass, this
finding appears to conflict with the domination by Pseudomonas
spp. of BAL samples in our study and of endotracheal aspirates in
a study of severe acute exacerbations of COPD [13]. However,
since COPD pathology may be anatomically heterogeneous, our
observation that the lung microarchitecture allows for the
development of distinct localized microbial communities during
disease provides a unifying hypothesis for all the culture-based
and -independent studies on the role of bacteria in COPD
progression.
The demonstration of spatially distinct bacterial communities in
the lungs may be very important to our understanding of
pulmonary health and disease because anatomic variation in the
microbiome is becoming the focus for dissecting disease mecha-
nisms at other body sites. For example, regions of skin prone to
dermatitis have been shown to have different microbial commu-
nities when compared to adjacent areas that remain disease-free
[37]. Similarly, differences between teeth in the structure of the
microbial community predisposes to disease within the same
mouth [38]. Mechanistically, the microbial communities in teeth
with periodontal disease are locally enriched for methanogenic
Archea when compared to those that are disease-free [38].
Although these organisms are not disease-causing, the evidence
suggests that they alter the local environment such that bacteria
known to cause disease can thrive. It is possible that similar
pathogenic syntropic interactions also exist in the lungs. We
observed the most striking microanatomic community differences
in the upper lobes of the lung, which is consistent with clinical
observations that emphysema in COPD most commonly begins in
the upper lobes.
Recognized limitations of our study include the absence of
oropharyngeal samples and the relatively small sample size. While
the latter is a matter for future studies, the former will be dealt with
here. The oropharyngeal sample as a control for microbiologic
studies of the lung is rooted in the belief that the lungs should be
sterile; thus, the purpose of the oropharyngeal sample is to rule
out contamination. However, despite the lack of this sample, we
can demonstrate that the lung microbiota that we have identified
is not the result of contamination. First, the levels of 16S detected
in subject BAL are too high to be consistent with contamination
(Figure 1), but high enough to be consistent with a low level
colonization. Second, the domination of Proteobacteria, in
particular Pseudomonas spp., in BAL samples is radically different
from the nasal cavity, which is dominated by the phylum
Actinobacteria [26], and the oropharynx, which is dominated by
Firmicutes [26]. In some subjects, Proteobacteria have been
shown to have a larger presence in the oropharynx, but
Pseudomonads were never encountered [26]. Finally, when the
airways from explanted lungs were sampled directly, the bacteria
identified were the same as those identified in BAL samples.
However, all of our advanced COPD explants lacked the
diversity observed in the ‘‘healthy smoker’’ controls. Collectively,
these data argue strongly that the airways of the lungs are an
independent microbial habitat, and that our results are not simply
a result of contamination.
In summary, these results demonstrate the need to consider, in a
systematic, anatomically-correlated fashion, both the lung micro-
biome and the host inflammatory response when studying COPD.
We believe that CT imaging will be central to this endeavor. By
demonstrating that one person’s lungs can harbor both general-
ized areas of ‘‘healthy’’ microbiome and a single site containing a
‘‘pathogenic’’ community, our results suggest a mechanism by
which the interaction of lung pathogens and host immunity might
contribute to localized disease progression, even in the absence of
overt exacerbation.
Table 5. Explant OTU Data.
Subject # Location OTUs.1% of Population
Diversity
(np-Shannon) OTUs
1.1%/Genera.1%
CS5 RUL Segmental 7 1.85 7/3
RUL Distal 4 1.11 4/1
RML Segmental 19 2.86 19/9
RML Distal 5 1.59 5/1
RLL Segmental 5 1.30 5/1
CS6 RUL Segmental 4 1.57 4/4
RUL Distal 11 2.48 11/7
RML Segmental 14 2.57 14/9
RML Distal 4 1.76 4/4
RLL Distal 11 2.61 11/6
Medial Upper Bronchus 5 1.26 5/4
LUL Segmental 9 1.73 9/3
LUL Distal 7 1.59 7/2
LLL Segmental 7 1.99 7/5
doi:10.1371/journal.pone.0016384.t005
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Table S1 Table S1 depicts the complete population breakdown
of the bacterial genera present in the lung explant tissue samples
shown in Figure 4.
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